Wegovy 0.5 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSYE5
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,998
Award facts
- Contract value 100% obligated
- $27,997.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $28,000 to AmerisourceBergen Drug Corp for the supply of Wegovy (semaglutide) 0.5 mg/0.5 mL pens on January 16, 2026, with an ultimate completion date of January 20, 2026. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 million vehicle through December 2031 that serves as the primary procurement mechanism for pharmaceutical products and medical supplies supporting military healthcare programs globally.
AmerisourceBergen Drug Corp functions as a critical pharmaceutical distributor within the federal medical supply chain, specializing in delivering a comprehensive range of brand-name and generic medications, vaccines, and medical devices to military treatment facilities and defense healthcare systems. The delivery order for Wegovy, an FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonist used in weight management and metabolic health treatment, reflects the expanding scope of pharmaceutical products being procured through DLA supply channels to support servicemembers and beneficiaries. The firm fixed-price structure and rapid delivery timeline (four days) indicate an urgent requirement for this specialty pharmaceutical product within the defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FSYE5?
SPE2DR26FSYE5 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26FSYE5 worth?
The government has obligated $27,998 on SPE2DR26FSYE5.
Is contract SPE2DR26FSYE5 an order under another contract?
Yes. SPE2DR26FSYE5 is a delivery order under SPE2DR25D1004, an indefinite delivery contract.
Was contract SPE2DR26FSYE5 competed?
The extent of competition for SPE2DR26FSYE5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award